L3VLUP
ProSign in

BDTX · AMGN in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

BDTXAMGN
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • BDTX
  • AMGN
0102030202120222023202420252026
Holders and value by quarter
QuarterBDTXAMGN
Q3 20201 holders, $16m16 holders, $16.3bn
Q4 20203 holders, $37m19 holders, $14.0bn
Q1 20211 holders, $1.6m16 holders, $14.5bn
Q2 20212 holders, $2.6m23 holders, $13.8bn
Q3 20211 holders, $862k24 holders, $11.6bn
Q4 2021none listed holders, n.a.21 holders, $10.4bn
Q1 2022none listed holders, n.a.23 holders, $9.9bn
Q2 2022none listed holders, n.a.28 holders, $9.7bn
Q3 2022none listed holders, n.a.21 holders, $7.9bn
Q4 2022none listed holders, n.a.24 holders, $9.3bn
Q1 2023none listed holders, n.a.22 holders, $8.4bn
Q2 20231 holders, $252k26 holders, $7.4bn
Q3 20232 holders, $5.0m26 holders, $8.7bn
Q4 20231 holders, $4.4m24 holders, $8.4bn
Q1 2024none listed holders, n.a.25 holders, $6.7bn
Q2 2024none listed holders, n.a.20 holders, $8.0bn
Q3 2024none listed holders, n.a.21 holders, $8.8bn
Q4 2024none listed holders, n.a.20 holders, $8.2bn
Q1 2025none listed holders, n.a.25 holders, $12.0bn
Q2 2025none listed holders, n.a.20 holders, $10.2bn
Q3 2025none listed holders, n.a.17 holders, $10.4bn
Q4 20251 holders, $1.0m19 holders, $18.0bn
Q1 2026none listed holders, n.a.15 holders, $21.4bn
Q2 2026none listed holders, n.a.23 holders, $24.9bn
BDTX

Black Diamond Therapeutics Inc

Holders
0
Reported value
$0
Buyers
n.a.
Sellers
n.a.

No cross-section for this quarter.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
AMGN

Amgen Inc

Holders
21
Reported value
$8.8bn
Buyers
16
Sellers
5

Breadth +11 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q3 2024

Among the 21 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only BDTX (0)

None.

Only AMGN (21)

AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., Dodge & Cox, Farallon Capital Management LLC, Fidelity (FMR LLC), Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Neuberger Berman Group LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Two Sigma Investments LP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →